Predictive modeling of neuroblastoma growth dynamics in xenograft model after bevacizumab anti-VEGF therapy
Y He, A Kodali, DI Wallace - Bulletin of Mathematical Biology, 2018 - Springer
Neuroblastoma is the leading cause of cancer death in young children. Although treatment
for neuroblastoma has improved, the 5-year survival rate of patients still remains less than …
for neuroblastoma has improved, the 5-year survival rate of patients still remains less than …
Anti-angiogenic drug scheduling optimisation with application to colorectal cancer
M Sturrock, IS Miller, G Kang, N Hannis Arba'ie… - Scientific reports, 2018 - nature.com
Bevacizumab (bvz) is a first choice anti-angiogenic drug in oncology and is primarily
administered in combination with chemotherapy. It has been hypothesized that anti …
administered in combination with chemotherapy. It has been hypothesized that anti …
SENSITIVITY OF COMBINED CHEMO-AND ANTIANGIOGENIC THERAPY RESULTS IN DIFFERENT MODELS DESCRIBING CANCER GROWTH.
M Dolbniak, M Kardynska… - Discrete & Continuous …, 2018 - search.ebscohost.com
This paper is concerned with analysis of two anticancer therapy models focused on
sensitivity of therapy outcome with respect to model structure and parameters. Realistic …
sensitivity of therapy outcome with respect to model structure and parameters. Realistic …